DUROS® technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months

Journal of Diabetes Science and Technology

Volumn 2, Issue 3, 2008, Pages 461-467

  Rohloff, Catherine M ^a   Alessi, Thomas R ^a   Yang, Bing ^a   Dahms, Janice ^a   Carr, John P ^a   Lautenbach, Scott D ^a  

^a Research Triangle   (United States)

Author keywords

Continuous peptide delivery; Drug delivery; GLP 1; Leuprolide; Omega interferon

Indexed keywords

EID: 79851476663     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200316     Document Type: Article

References (10)

1. Hall SC, Tan MM, Leonard JJ, Stevenson CL. Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide. J Pept Res. 1999;53(4);432-41.
2. Fowler JE Jr, Gottesman JE, Reid CF, Andriole GL Jr, Soloway MS. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol. 2000;164(3 Pt 1);730-4.
3. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22(7);1137-43.
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4);1409-39.
5. Novozhenov V, Zakharova N, Vinogradova E, Nikitin I, Gorbakov V, Yakovlev A, Pak S, Rafalski V, Bogomolov P, Alessi T, Blanchett D, Lang W, Langecker P, McNally J, McHutchison J. Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis c genotype-1 infection. 42nd Annual Meeting of the European Association for the Study of the Liver (EASL); 2007.
6. Buckwold VE, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega interferon produced from CHO-SS cells. Basic Clin Pharmacol Toxicol. 2006;99(1);62-70.
7. Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res. 2007;73(2);118-25.
8. Berry SA, Fereira P, Tan M, Kang L, Dehnad H, Chen G, Ayer R, Wright J, Stevenson C. To investigate zero order delivery profiles of protein/peptide suspension formulations from osmotically driven implantable pumps. American Association Pharmaceutical Scientists 2000 Annual Meeting; October 2000, Abstract 2248.
9. Wright JC, Tao Leonard S, Stevenson CL, Beck JC, Chen G, Jao RM, Johnson PA, Leonard J, Skowronski RJ. An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release. 2001;75(1-2):1-10.
10. Fowler JE Jr; Viadur Study Group. Patient-reported experience with the Viadur 12-month leuprolide implant for prostate cancer. Urology. 2001;58(3):430-4.